APOE in Alzheimer's Disease: Genetic Variants, Mechanisms, and Therapeutic Implications

Released: May 20, 2025 |

Length: 8 pages |

Language: English |

Resource: Whitepaper

With the number of individuals with Alzheimer's disease (AD) and other dementias expected to triple over the next few decades, there is a push to unravel the brain changes involved with the disease. The genetics of AD is complex, but one gene, Apolipoprotein E (APOE) ε4, is known to be the strongest genetic risk factor for AD.

Carriers of the APOE ε4 allele face higher risk for developing AD due to amyloid buildup, neuroinflammation, and tau pathology all while facing higher risk of treatment complications. Knowing who carries the APOE e4 allele and who develops AD—and how they can be treated—is an active area of investigation.

Email Address *

First Name *

Last Name *

Job Title *

Company Name *

Country *

State/Province

Zip/Postcode *

Industry

Job Function *

I would like to be contacted by a Beckman Coulter Representative to learn more about RUO Neurodegenerative disease assays. *

By requesting this resource you agree to our terms of use. All data is protected by our Privacy Notice.

By submitting this form, you are confirming you are an adult of 18 years or older and you agree to Beckman Coulter contacting you with marketing-related emails or by telephone. You may unsubscribe at any time. Beckman Coulter websites and communications are subject to their Privacy Notice.

Please agree to the conditions